Search Results

You are looking at 1 - 1 of 1 items for

  • Author: S Shafaeizadeh x
  • Refine by access: All content x
Clear All Modify Search
H Y Li Laboratory of Metabolic Medicine, Singapore Bioimaging Consortium, A*STAR, Singapore, Republic of Singapore

Search for other papers by H Y Li in
Google Scholar
PubMed
Close
,
Y X Liu Laboratory of Metabolic Medicine, Singapore Bioimaging Consortium, A*STAR, Singapore, Republic of Singapore
Danone Nutricia Research, Singapore, Republic of Singapore

Search for other papers by Y X Liu in
Google Scholar
PubMed
Close
,
L Harvey Danone Nutricia Research, Utrecht, The Netherlands

Search for other papers by L Harvey in
Google Scholar
PubMed
Close
,
S Shafaeizadeh Danone Nutricia Research, Utrecht, The Netherlands

Search for other papers by S Shafaeizadeh in
Google Scholar
PubMed
Close
,
E M van der Beek Danone Nutricia Research, Utrecht, The Netherlands
Department of Pediatrics, University Medical Centre Groningen, Groningen, The Netherlands

Search for other papers by E M van der Beek in
Google Scholar
PubMed
Close
, and
W Han Laboratory of Metabolic Medicine, Singapore Bioimaging Consortium, A*STAR, Singapore, Republic of Singapore
Institute of Molecular and Cell Biology, A*STAR, Singapore, Republic of Singapore
School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

Search for other papers by W Han in
Google Scholar
PubMed
Close

The prevalence of gestational diabetes mellitus (GDM) is estimated at 14% globally, and in some countries, such as Singapore, exceeds 20%. Both women and children exposed to GDM have an increased risk of later metabolic diseases, cardiovascular disease and other health issues. Beyond lifestyle changes and pharmaceutical intervention using existing type 2 diabetes medications for expecting women, there are limited treatment options for women with GDM; targeting better outcomes of potentially affected infants is unexplored. Numerous animal models have been generated for understanding of pathological processes of GDM development and for development of treatment strategies. These models, however, suffer from limited windows of opportunity to examine risk factors and potential intervention options. By combining short-term high-fat diet (HFD) feeding and low-dose streptozotocin (STZ) treatments before pregnancy, we have established a mouse model with marked transient gestation-specific hyperglycemia, which allows testing of nutritional and pharmacological interventions before, during and beyond pregnancy.

Restricted access